In addition, therapeutic strategies for short-term anti-S100A9 blockade during the early inflammatory phase post-MI can effectively mitigated post-ischemic myocardial damage, while long-term blockade may induce undesired side effects and offset the favorable consequences of short-term treatment. Here, S100A9 is linked to myocardial infarction.